Avanos Medical (AVNS) Depreciation & Amortization (CF) (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $10.2 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 6.25% year-over-year to $10.2 million; the trailing twelve-month figure through Mar 2026 stood at $39.5 million (down 9.61% YoY), and the FY2025 full-year result was $38.9 million, down 14.51% from the prior year.
• Depreciation & Amortization (CF) climbed to $10.2 million in Q1 2026, from $9.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $13.4 million in Q4 2022 to a low of $9.4 million in Q3 2025.
• A 5-year average of $11.1 million and a median of $11.3 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 41.05% in 2022 and decreased 19.66% in 2025, its largest moves.
• Tracing AVNS's Depreciation & Amortization (CF) over 5 years: stood at $13.4 million in 2022, then decreased by 14.18% to $11.5 million in 2023, then dropped by 3.48% to $11.1 million in 2024, then slipped by 10.81% to $9.9 million in 2025, then grew by 3.03% to $10.2 million in 2026.
• Business Quant data shows AVNS's Depreciation & Amortization (CF) at $10.2 million in Q1 2026, $9.9 million in Q4 2025, and $9.4 million in Q3 2025.